Vernalis Research Limited

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Robert Mark Pratt

Claire Elizabeth Dawson

Jonathan Mark Bentley

Suneel Gaur

Stephan Roever

Roger John Gillespie

David Reginald Adams

Howard Langham Mansell

Jonathan Richard Anthony Roffey

James Edward Paul Davidson

Joanne Lerpiniere

Nathaniel Monck

Ashley Roger George

Matthias Heinrich Nettekoven

Patrizio Mattei

Hans G Richter

Paul Hebeisen

Wolfgang Guba

Henri Stalder

Jean-Luc Specklin

Richard John Hamlyn

Gemma Caroline Stratton

Scott Murray Weiss

Matthew Alexander James Duncton

Jacques Mizrahi

David Bebbington

Vicki Ruston

Victoria Jane Ruston

Sukhjit Sohal

Kerry Wilkinson

Kerry Harrison

Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CBreceptors such as obesity: Formula (I) wherein: Rand Rare independently selected from aryl; and Ris hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of Rand Rhas a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [&#x2014;CH&#x2014;O&#x2014;] group. 

Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders

Use of a compound of formula (I) wherein Ris selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NRR, NRCOR, NRCONRR, NRCORand NRSOR; Ris selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; Ris selected from H, alkyl, COR, CONRR, CONRNRR, CORand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an (NRR) group then Rand Rmay be linked to form a heterocyclic ring; Ris selected from alkyl and aryl; R, Rand Rare independently selected from H, alkyl and aryl, or Rand Rmay be linked to form a heterocyclic ring, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and R, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 

Purine derivatives as purinergic receptor antagonists

A compound of formula (I), wherein X is S or O; Ris selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR, COR, CONRR, CONRNRR, NRR, NRCONRR, NRCOR, NRCOR, and NRSOR; Ris selected from aryl attached via an unsaturated carbon atom; Ris selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO; Ris selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO, COR, COR, CONRR, CONRNRR, NRR, NRCONRR, NRCOR, NRCORand NRSOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an (NRR) group, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, and the use thereof in therapy and in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such a Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or wherein said medicament is for neuroprotection in a subject 

Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists

The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein Rto Rhave the significance given in claim. These compounds can be used for the preparation of medicaments.

Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity

The present invention is a chemical compound of formula (I)or a pharmaceutically acceptable salts, solvates and esters thereof, wherein Rto R, A, Am and n are as described in the specification.

Piperazine derivatives

Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands

Growing community of inventors

Wokingham, United Kingdom

Robert Mark Pratt